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PRM5
INCORPORATING EQUITY INTO DEVELOPING AND IMPLEMENTING EVIDENCE-
BASED CLINICAL PRACTICE GUIDELINES
Eslava-Schmalbach JH, Sandoval Vargas G, Mosquera PA
Universidad Nacional de Colombia, Bogotá, Colombia
BACKGROUND: Clinical practice guidelines (CPG) are useful tools for clinical deci-
sion making, processes standardization and quality of care improvements. The
current General Social Security and Health System (GSSHS) in Colombia is promot-
ing the initiative of developing and implementing CPG based on evidence in order
to improve efficiency and quality of care. The reduction of inequalities in health
should be an objective of the GSSHS. OBJECTIVES: The main propose of this anal-
ysis is to argue why it is necessary to consider the incorporation of equity consid-
erations in the development and implementation of clinical practice guidelines
based on the evidence. METHODS: A series of reflections were made. Narrative
description was used for showing the arguments that support the main findings.
RESULTS: Among the main findings are: 1) Differential effectiveness by social
groups of interventions could diminish final effectiveness of CPG in the GSSHS; 2)
To not consider geographical, ethnic, socioeconomic, cultural and access diversity
issues within the CPG could have a potential negative impacts of the CPG; 3) Overall
effectiveness of GPC could be better if equity issues are included in the quality
verification checklist of the guideline questions; and 4) Incorporating equity issues
in the process of developing CPG could be cost effective, because improve overall
effectiveness of CPG. CONCLUSIONS: To include equity issues in CPG and can help
in achieving more equitable health outcomes. From this point of view CPG could be
key tools to promote equity in care and health outcomes. Keywords: health in-
equalities, clinical practice guidelines, essay (Source: MeSH, NLM).
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TRANSLATION OF PATIENT-REPORTED OUTCOMES MEASURES
TRANSLATABILITY REVIEW AND ITEM DEFINITION
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Translatability Review and Item Definition documents are key components to any
successful Patient Reported Outcome (PRO) translation and are especially relevant
in item banking initiatives. Translatability review helps to ensure concepts, con-
structs and phrasing in the source language are appropriate for translation into
other languages and for multicultural contexts. Identifying potential issues during
item development can result in improvement of the source item. When modifica-
tion of the source is not possible or necessary, translatability review can be seen as
a first step towards identifying acceptable translation alternatives which can be
used by linguists. The assessment of item translatability before the translation
process begins also facilitates the creation of item definitions, a critical tool for
increasing translation accuracy. The Item Definition document refers to the iden-
tification and clarification of concepts the items are trying to measure. The devel-
opment of item definitions is an iterative process combining efforts by translation
coordinators and item/questionnaire developers as well as input from linguists.
These steps are especially essential in item banking initiatives in which items are
frequently made available by different developers and sources on behalf of varying
patient populations, with disparate answer categories. As translation of PRO mea-
sures is much more than just a literal, word for word translation process, these
steps are fundamental in furthering the equivalence, comparability and data
poolability of translated language versions. This presentation will provide infor-
mation regarding when to carry out these steps, how to carry them out and who
should be involved in them. Linguistic issues such as, but not limited to, sentence
structure, register and ambiguity will be discussed. Examples from National Insti-
tutes of Health Spanish translation projects Patient-Reported Outcomes version of
the Common Terminology Criteria for Adverse Events (PRO-CTCAE) and The Pa-
tient-Reported Outcomes Measurement Information System (PROMIS) will be high-
lighted.
Respiratory-Related Disorders – Cost Studies
PRS1
BUDGET IMPACT ANALYSIS OF FLUTICASONE FUROATE (FFNS) IN TREATMENT
OF ALLERGIC RHINITIS PATIENTS IN MEXICO
Rely K1, Salinas GE2, Anaya P3, Alexandre PK4
1CEAHealthTech, México, D.F., México, 2Hospital Infantil de México Federico Gómez, Secretaría
de Salud, México, D.F., México, 3GlaxoSmithKline México, México, D.F., México, 4Johns Hopkins
University, Baltimore, MD, USA OBJECTIVES: To estimate the 5-year projected impact
on the annual pharmacy budget for allergic rhinitis (AR) patients in Mexico.
METHODS: Mexican prevalence and treatment data for AR patients were obtained
from published and nonpublished sources. The model considered 2 scenarios—
without (pre) and with (post) FFNS. Market share data for corticosteroid treatment
options for AR pre-FFNS and in the first year post-FFNS were obtained from non-
published, real-world drug utilization data collected by GSK. Market shares for the
second until fifth years post- FFNS were forecasted by the study authors. Drug costs
were based on the Mexican Social Security Institute (IMSS). Wholesale Acquisition
Cost was accessed on March 2010. The results for each indication were analyzed
individually and summed to reflect the total impact of FFNS. Results were also
considered on a per member per month (PMPM) basis to examine the relative
impact on the plan. Sensitivity analyses were performed by varying several model
input parameters. RESULTS: The estimated prevalence of AR in 2010 was 10%. In
the year after its introduction, 60% of the AR population filled a prescription for
FFNS. The estimated total cost for AR treatment prior to introduction of FFNS was
$ 552 million and (532 to $ 384 million post FFNS. The incremental decrease in
pharmacy benefit cost was ($ 20 to $ 84 millions) in 2010 dollars. These reductions
translated to a medical care cost saving of $ 266 millions over 5 years.
CONCLUSIONS:Model results suggest that increasing the use of fluticasone furoate
decreases total budget costs due to decreased acquisition drug costs.
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COSTOS DE ATENCION MEDICA ATRIBUIBLES AL CONSUMO DE TABACO EN
MÉXICO
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OBJECTIVOS: Estimar la carga económica, en términos de costos de atención
médica que las enfermedades atribuibles al consumo de tabaco representan para el
sistema de salud Mexicano. METODOLOGÍAS: La estimación del costo directo de
atención médica atribuible al tabaquismo se realizó con las enfermedades: CP, IAM,
EPOC y EVC, en 2009. Instituciones de salud participantes: institutos nacionales
(INNN, INCAN, INER e INCAR), Hospital Central Militar (HCM), Instituto de Seguri-
dad y Servicios Sociales de los Trabajadores del Estado (sólo incluye al CMN “20 de
Noviembre” y al HRZ “1°. de Octubre” del ISSSTE) e Instituto Mexicano del Seguro
Social (IMSS). El análisis de costos fue realizado desde la perspectiva del proveedor
de servicios, utilizando la metodología Cost of Illness, basada en la prevalencia así
como la creación de un panel de expertos multidisciplinario, que clasificó la aten-
ción médica: Ambulatoria, Urgencias, Hospitalización, Quirófano, Unidad de Cui-
dados Intensivos, Quimioterapia, Cuidados Paliativos y Radioterapia. Finalmente
empleamos la fracción atribuible por tabaco para estimar dichos costos. Los costos
están expresados en pesos mexicanos ($) y en dólares americanos (USD) del 2009.
RESULTADOS: Los costos institucionales de atención médica por tabaquismo as-
cendieron a $459,026,446.2 (35,131,636.3 USD); Institutos Nacionales, $92,016,175.0
(7,042,467.4 USD); HCM, $103,483,466.1 (7,920,117.7 USD); ISSSTE y $9,564,089,959.0
(731,988,608.4 USD); IMSS, respectivamente. Los costos nacionales por tabaquismo
oscilaron entre $30,213,184,046.5 (2,312,369,147.7 USD) y $44,484,500,278.1
(3,404,625,802.9 USD). El IAM y el CP fueron los más caros. CONCLUSIONES: Nues-
tros resultados muestran la elevada carga económica que representan para el sis-
tema de salud mexicano el tabaquismo y son evidencia científica sobre la magnitud
del problema. Como las enfermedades asociadas al tabaquismo son prevenibles,
una adecuada política de salud para el control del tabaco, produciría una reasig-
nación de los recursos económicos que actualmente se destinan al tratamiento de
las enfermedades provocadas por el tabaco hacia otros programas institucionales.
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COSTOS DE ATENCION MEDICA DE LA ENFERMEDAD PULMONAR
OBSTRUCTIVA CRONICA ATRIBUIBLES AL TABACO
Ramirez-Venegas A1, Quintana Carrillo R2, Sansores R1, Hernandez-Zenteno R1,
Reynales Shigematsu L2
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OBJECTIVOS: Estimar los costos directos de atención médica de la Enfermedad
Pulmonar Obstructiva Crónica (EPOC) asociados al consumo de tabaco, en el Insti-
tuto Nacional de Enfermedades Respiratorias.METODOLOGÍAS:Durante el 2009 se
estimaron los costos directos de la EPOC de los pacientes que fueron atendidos en
el año 2008 en el Instituto. El análisis de costos se hizo desde la perspectiva del
proveedor de servicios, considerando el enfoque de la metodología Cost of Illness
(COI), basada en la prevalencia así como la creación de un panel de expertos mul-
tidisciplinario, que clasificó la atención médica en 4 eventos: Ambulatoria, Urgen-
cias, Hospitalización y Unidad de Cuidados Intensivos. Finalmente empleamos la
fracción atribuible por tabaco para estimar los costos por consumo de tabaco. El
costo además se estimo de acuerdo a la gravedad de la enfermedad con los criterios
GOLD. RESULTADOS: El costo anual de la EPOC atribuible al tabaco fue de $36
millones. El costo promedio por paciente, de acuerdo a GOLD fue de $30 mil; estadio
I, $37 mil; estadio II, $84 mil; estadio III y $288 mil; estadio IV. Entre más grave fue
la enfermedad, (III y IV) mayores costos resultaron. CONCLUSIONES: La evaluación
económica de los costos directos que ocasiona el EPOC debido al tabaquismo, con-
firma la gran carga económica que representan estos pacientes para el presupuesto
del INER y del sistema de salud mexicano. Estos resultados proveen suficiente
evidencia científica para apoyar la implementación de políticas del sector salud
relacionadas con el tabaco.
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ECONOMIC EVALUATION OF THE USE OF PALIVIZUMAB AS PROPHYLACTIC
TREATMENT FOR THE REDUCTION OF COMPLICATIONS ASSOCIATED WITH
RESPIRATORY SYNCYTIAL VIRUS IN PRE-TERM PATIENTS
Mayen-Herrera E1, Buesch K2, Cortina D3
1Abbott Laboratories de México, México, D.F. México, 2●●●, 3●●●
OBJECTIVES: To determine the incremental cost-effectiveness ratio (ICER) of the
use of palivizumab as prophylaxis for the reduction of complications associated
with respiratory syncytial virus (RSV) in pre-term patients29 weeks of gestational
age (WGA) under the Mexican public health sector perspective. METHODS: A cost-
utility model was developed based on a decision tree that evaluated both scenarios
of prophylaxis and no-prophylaxis. Epidemiological and cost data were obtained
from different Mexican sources such as the Mexican Institute of Social Security
(IMSS) by analysing birth rates. Clinical effectiveness was obtained from the inter-
national literature (Cardiac Synagis Study Group, The IMpact-RSV Study Group
MEDI-493 Study Group). Prophylaxis therapy consisted of 5 applications of palivi-
zumab during the winter season in Mexico. The dose scheme considered was 15
mg/kg. The effectiveness outcomes were quality adjusted life years (QALYs). Since
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